Bayer | BAYN - Equity Capital And Reserves


Bayer reported EUR28.85B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Air Liquide EUR 26.21B 1.7B Dec/2025
Akzo Nobel EUR 4.88B 222M Mar/2026
Alcon AG USD 22.13B 99M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
Arkema EUR 6.96B 913.9M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
BASF EUR 33.2B 434M Dec/2025
Bayer EUR 28.85B 2.9B Mar/2026
Beiersdorf EUR 8.6B 133M Dec/2025
Corteva USD 24.36B 218M Mar/2026
Covestro EUR 7B 908M Dec/2025
Essilor EUR 38.89B 1.07B Dec/2025
Fresenius EUR 19.77B 1.14B Dec/2025
Fresenius Medical Care EUR 14.2B 13.95B Mar/2026
Genmab DKK 5.85B 96M Dec/2025
Givaudan CHF 4.54B 430M Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
GRIFOLS EUR 5.46B 171M Mar/2026
Henkel EUR 20.5B 459M Dec/2025
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Johnson Matthey GBP 2.02B 85M Jun/2026
Linde USD 38.25B 1.84B Dec/2025
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 29.74B 1.15B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Nutrien USD 25.15B 169M Mar/2026
Philips EUR 11.39B 403M Mar/2026
PPG Industries USD 8.1B 163M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
SAP EUR 44.86B 109M Mar/2026
Solvay EUR 1.18B 161M Mar/2026
UCB EUR 10.87B 1.18B Dec/2025
Umicore EUR 2.24B 195.4M Dec/2025
Vinci EUR 34.33B 5.71B Dec/2025